Innovent Announces Phase 1 Clinical Data of IBI322  ( CD47/PD-L1 Bispecific Antibody )  in the Treatment of Anti-PD- ( L ) 1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting